Literature DB >> 2908715

Hemodynamic responses to different levels of alpha-adrenergic interruption in congestive heart failure.

A P Good1, D V Unverferth, C V Leier.   

Abstract

The effects of prazosin, clonidine, and indoramin on central and regional hemodynamic parameters and left ventricular performance were analyzed in a congestive heart failure population to compare the pharmacodynamic responses to different levels of alpha-adrenergic interruption in this condition. The sympathetic nervous system is blocked at the peripheral alpha1-receptor by prazosin, at central nervous system alpha-receptor sites (via alpha-adrenoceptor agonism) by clonidine, and at peripheral and central sites by indoramin. Prazosin and indoramin produced reductions in total systemic and pulmonary vascular resistances, mean systemic and pulmonary artery pressures, and pulmonary capillary wedge pressure with little change in heart rate. Both agents selectively increased hepatic blood flow. Clonidine also decreased pulmonary artery pressure and vascular resistance, but evoked negative inotropic and chronotropic activity and did not alter regional blood flow. In contrast to prazosin, indoramin and clonidine did not augment cardiac output or stroke volume. In the setting of congestive heart failure, the central and regional hemodynamic effects and the responses in left ventricular performance vary considerably depending on the site of alpha-adrenergic interruption.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2908715     DOI: 10.1007/BF02125736

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  21 in total

1.  Central and peripheral contribution to the antihypertensive action of indoramin.

Authors:  T Baum; A T Shropshire
Journal:  Eur J Pharmacol       Date:  1975-05       Impact factor: 4.432

2.  Preliminary observations of chronic indoramin therapy in congestive heart failure.

Authors:  C V Leier; P Huss; D Parrish; P F Binkley; D V Unverferth
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

3.  The clinical pharmacology of indoramin.

Authors:  R G Shanks
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

4.  Clinical pharmacology and therapeutic application of prazosin in acute and chronic refractory congestive heart failure. Balanced systemic venous and arterial dilation improving pulmonary congestion and cardiac output.

Authors:  N A Awan; R R Miller; M P Miller; K Specht; Z Vera; D T Mason
Journal:  Am J Med       Date:  1978-07       Impact factor: 4.965

5.  Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose.

Authors:  R D Magorien; D W Triffon; C E Desch; W H Bay; D V Unverferth; C V Leier
Journal:  Ann Intern Med       Date:  1981-07       Impact factor: 25.391

6.  Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting of congestive heart failure.

Authors:  C V Leier; C E Desch; R D Magorien; D W Triffon; D V Unverferth; H Boudoulas; R P Lewis
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

7.  CNS site of clonidine induced hypotension: a microiontophoretic study of bulbar cardiovascular neurons.

Authors:  J N Sharma; B B Sandrew; S C Wang
Journal:  Brain Res       Date:  1978-07-28       Impact factor: 3.252

8.  Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure.

Authors:  M E Leithe; R D Margorien; J B Hermiller; D V Unverferth; C V Leier
Journal:  Circulation       Date:  1984-01       Impact factor: 29.690

Review 9.  Drugs five years later: clonidine.

Authors:  J Lowenstein
Journal:  Ann Intern Med       Date:  1980-01       Impact factor: 25.391

Review 10.  Physiologic and pharmacologic determinants of vasodilator response: a conceptual framework for rational drug therapy for chronic heart failure.

Authors:  M Packer; T H Le Jemtel
Journal:  Prog Cardiovasc Dis       Date:  1982 Jan-Feb       Impact factor: 8.194

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.